Xenograft bioprosthetic heart valves: Past, present and future

International Journal of Surgery

Volumn 23, Issue , 2015, Pages 280-284

  Manji, Rizwan A ^a,b   Lee, Whayoung ^c   Cooper, David K C ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Calcification; Gal; Genetically modified; Glutaraldehyde; Heart valves; NeuGc; Pigs; Xenograft rejection

Indexed keywords

GLUTARALDEHYDE;

ANTIGEN EXPRESSION; AORTA VALVE REPLACEMENT; ASCENDING AORTA; CALCIFICATION; DEVICE FAILURE; GENETIC ENGINEERING; GRAFT FAILURE; HEART VALVE BIOPROSTHESIS; HEART VALVE REPLACEMENT; HEART VALVE SURGERY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROSTHETIC VALVE DYSFUNCTION; REVIEW; VALVE DETERIORATION; XENOTRANSPLANTATION; ADVERSE EFFECTS; ANIMAL; BIOPROSTHESIS; CALCINOSIS; GRAFT REJECTION; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; IMMUNOLOGY; PIG; PROCEDURES; TRANSGENIC ANIMAL; TRENDS; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOPROSTHESIS; CALCINOSIS; GRAFT REJECTION; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HETEROGRAFTS; HUMANS; SWINE;

EID: 84951573643     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2015.07.009     Document Type: Review

References (42)

1. Siddiqui R.F., Abraham J.R., Butany J. Bioprosthetic heart valves: modes of failure. Histopathology 2009, 55:135-144.
2. Binet J.P., Carpentier A., Langlois J., Duran C., Colvez P. Implantation of heterogenic valves in the treatment of aortic cardiopathies. C. R. Acad. Sci. Hebd. Seances Acad. Sci. D. 1965, 261:5733-5734.
3. Carpentier A., Lemaigre G., Robert L., Carpentier S., Dubost C. Biological factors affecting long-term results of valvular heterografts. J. Thorac. Cardiovasc. Surg. 1969, 58:467-483.
4. Carpentier A., Deloche A., Relland J., Fabiani J.N., Forman J., Camilleri J.P., et al. Six-year follow-up of glutaraldehyde-preserved heterografts. With particular reference to the treatment of congenital valve malformations. J. Thorac. Cardiovasc. Surg. 1974, 68:771-782.
5. Schoen F.J., Levy R.J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann. Thorac. Surg. 2005, 79:1072-1080.
6. Schoen F.J., Levy R.J. Pathophysiology of Bioprosthetic Heart Valve Calcification, Biological and Bioprosthetic Valves 1986, New York.
7. Simionescu D.T. Prevention of calcification in bioprosthetic heart valves: challenges and perspectives. Expert Opin. Biol. Ther. 2004, 4:1971-1985.
8. Reul G.J., Cooley D.A., Duncan J.M., Frazier O.H., Hallman G.L., Livesay J.J., et al. Valve failure with the Ionescu-Shiley bovine pericardial bioprosthesis: analysis of 2680 patients. J. Vasc. Surg. 1985, 2:192-204.
9. Diaz-Jauanen E., Strickland R.G., Williams R.C. Studies of human lymphocytes in the newborn and the aged. Am. J. Med. 1975, 58:620-628.
10. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2302-2309.
11. Doherty T.M., Asotra K., Fitzpatrick L.A., Qiao J.H., Wilkin D.J., Detrano R.C., et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11201-11206.
12. Basaraba R.J., Bielefeldt-Ohmann H., Eschelbach E.K., Reisenhauer C., Tolnay A.E., Taraba L.C., et al. Increased expression of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig. Tuberc. Edinb. 2008, 88:69-79.
13. Chang Q., Jing H., Sun M., Xu P. Exploring the role of short-course cyclosporin a therapy in preventing homograft valve calcification after transplantation. Cell. Immunol. 2014, 287:36-45.
14. Stein P.D., Wang C.H., Riddle J.M., Magilligan D.J. Leukocytes, platelets, and surface microstructure of spontaneously degenerated porcine bioprosthetic valves. J. Card. Surg. 1988, 3:253-261.
15. Dahm M., Lyman W.D., Schwell A.B., Factor S.M., Frater R.W. Immunogenicity of glutaraldehyde-tanned bovine pericardium. J. Thorac. Cardiovasc. Surg. 1990, 99:1082-1090.
16. Vincentelli A., Latremouille C., Zegdi R., Shen M., Lajos P.S., Chachques J.C., et al. Does glutaraldehyde induce calcification of bioprosthetic tissues?. Ann. Thorac. Surg. 1998, 66:S255-S258.
17. Grabenwoger M., Fitzal F., Gross C., Hutschala D., Bock P., Brucke P., et al. Different modes of degeneration in autologous and heterologous heart valve prostheses. J. Heart Valve Dis. 2000, 9:104-109. discussion 110-101.
18. Manji R.A., Zhu L.F., Nijjar N.K., Rayner D.C., Korbutt G.S., Churchill T.A., et al. Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation 2006, 114:318-327.
19. Kobayashi T., Cooper D.K. Anti-Gal, alpha-Gal epitopes, and xenotransplantation. Subcell. Biochem. 1999, 32:229-257.
20. Phelps C.J., Koike C., Vaught T.D., Boone J., Wells K.D., Chen S.H., et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003, 299:411-414.
21. Kuwaki K., Tseng Y.L., Dor F.J., Shimizu A., Houser S.L., Sanderson T.M., et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat. Med. 2005, 11:29-31.
22. Park C.S., Park S.S., Choi S.Y., Yoon S.H., Kim W.H., Kim Y.J. Anti alpha-gal immune response following porcine bioprosthesis implantation in children. J. Heart Valve Dis. 2010, 19:124-130.
23. Naso F., Gandaglia A., Bottio T., Tarzia V., Nottle M.B., d'Apice A.J., et al. First quantification of alpha-Gal epitope in current glutaraldehyde-fixed heart valve bioprostheses. Xenotransplantation 2013, 20:252-261.
24. Bloch O., Golde P., Dohmen P.M., Posner S., Konertz W., Erdbrugger W. Immune response in patients receiving a bioprosthetic heart valve: lack of response with decellularized valves. Tissue Eng. Part A 2011, 17:2399-2405.
25. Konakci K.Z., Bohle B., Blumer R., Hoetzenecker W., Roth G., Moser B., et al. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur. J. Clin. Invest. 2005, 35:17-23.
26. McGregor C.G., Kogelberg H., Vlasin M., Byrne G.W. Gal-knockout bioprostheses exhibit less immune stimulation compared to standard biological heart valves. J. Heart Valve Dis. 2013, 22:383-390.
27. Lim H.G., Choi S.Y., Yoon E.J., Kim S.H., Kim Y.J. In vivo efficacy of alpha-galactosidase as possible promise for prolonged durability of bioprosthetic heart valve using alpha1,3-galactosyltransferase knockout mouse. Tissue Eng. Part A 2013, 19:2339-2348.
28. McGregor C.G., Carpentier A., Lila N., Logan J.S., Byrne G.W. Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves. J. Thorac. Cardiovasc. Surg. 2011, 141:269-275.
29. Lila N., McGregor C.G., Carpentier S., Rancic J., Byrne G.W., Carpentier A. Gal knockout pig pericardium: new source of material for heart valve bioprostheses. J. Heart Lung Transpl. 2010, 29:538-543.
30. Cooper D.K. How important is the anti-Gal antibody response following the implantation of a porcine bioprosthesis?. J. Heart Valve Dis. 2009, 18:671-672.
31. Barone A., Benktander J., Teneberg S., Breimer M.E. Characterization of acid and non-acid glycosphingolipids of porcine heart valve cusps as potential immune targets in biological heart valve grafts. Xenotransplantation 2014, 21:510-522.
32. Bouhours D., Pourcel C., Bouhours J.-F. Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Galα1-3Gal), blood group H determinant and N-glycolylneuraminic acid. Glycoconj. J. 1996, 13:947-953.
33. Zhu A., Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002, 9:376-381.
34. Salama A., Evanno G., Harb J., Soulillou J.P. Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation. Xenotransplantation 2015, 22:85-94.
35. Springer S.A., Diaz S.L., Gagneux P. Parallel evolution of a self-signal: humans and new world monkeys independently lost the cell surface sugar Neu5Gc. Immunogenetics 2014, 66:671-674.
36. Samraj A.N., Pearce O.M., Laubli H., Crittenden A.N., Bergfeld A.K., Banda K., et al. A red meat-derived glycan promotes inflammation and cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:542-547.
37. Scobie L., Padler-Karavani V., Le Bas-Bernardet S., Crossan C., Blaha J., Matouskova M., et al. Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts. J. Immunol. 2013, 191:2907-2915.
38. Jeong H.J., Adhya M., Park H.M., Kim Y.G., Kim B.G. Detection of Hanganutziu-Deicher antigens in O-glycans from pig heart tissues by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Xenotransplantation 2013, 20:407-417.
39. Lee W., Hara H., Cooper D.K., Manji R.A. Expression of NeuGc on pig heart valves. Xenotransplantation 2015, 22:153-154.
40. Lutz A.J., Li P., Estrada J.L., Sidner R.A., Chihara R.K., Downey S.M., et al. Double knockout pigs deficient in N-glycolylneuraminic acid and galactose alpha-1,3-galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation 2013, 20:27-35.
41. Cooper D.K., Ekser B., Burlak C., Ezzelarab M., Hara H., Paris L., et al. Clinical lung xenotransplantation-what donor genetic modifications may be necessary?. Xenotransplantation 2012, 19:144-158.
42. Wilczek P., Lesiak A., Niemiec-Cyganek A., Kubin B., Slomski R., Nozynski J., et al. Biomechanical properties of hybrid heart valve prosthesis utilizing the pigs that do not express the galactose-alpha-1,3-galactose (alpha-Gal) antigen derived tissue and tissue engineering technique. J. Mater. Sci. Mater. Med. 2015, 26:5329.